Anti-F8 Recombinant Antibody Products

Loading...

Anti-F8 Products

+ Filter

Loading...

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.

Specialized in Hematology, Creative Biolabs has engineered ultra-specific anti-F8 recombinant antibodies. As the naturally occurring cofactor missing in Hemophilia A, Coagulation Factor VIII (F8) is a central player in bleeding disorder research and the development of biotherapeutics targeting these proteins. Creative Biolabs’ high-quality recombinant antibodies are a diagnostic tool for F8 deficiency and inhibitor formation, and an invaluable resource for the development of next generation F8-mimetic therapeutics.

F8: The Anti-Hemophilic Factor A

Coagulation Factor VIII (F8) is a large, complex glycoprotein circulating in the plasma as an inactive procofactor bound to von Willebrand factor (vWF) which prevents it from degradation. F8, like Factor V, is a procofactor, and it is converted into the active cofactor, Factor VIIIa (F8a), after cleavage by thrombin. The activated Factor VIIIa then acts as the cofactor for the enzyme Factor IXa, which are bound to the platelet surface. The F8a/F9a enzyme complex is referred to as the “tenase complex”, and is the enzyme complex responsible for the activation of Factor X. Genetic deficiency or dysfunction of the Factor VIII protein severs this intrinsic pathway and results in Hemophilia A, a severe bleeding disorder.

Alternative Names

AHF; F8B; F8C; HEMA; FVIII; DXS1253E; coagulation factor VIII; antihemophilic factor; coagulation factor VIII A1 domain; coagulation factor VIII C2 domain; coagulation factor VIII, procoagulant component; coagulation factor VIIIc; factor VIII F8B; Factor VIII

Background

This gene encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. This gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity. Defects in this gene results in hemophilia A, a common recessive X-linked coagulation disorder.

Anti-F8 rAb Products

Creative Biolabs’ anti-F8 recombinant antibodies are specifically engineered for high specificity and performance and are rigorously validated for accurate detection of Factor VIII in plasma. Our anti-F8 recombinant antibodies are optimized for use in ELISA assays for the diagnosis of hemophilia and in Bethesda assays to detect the titer of the inhibitory autoantibodies that form in these patients, providing the consistency and specificity required for clinical diagnostic assays and hemophilia research.

Table 1. Featured anti-F8 recombinant antibody products at Creative Biolabs.

Creative Quality Control

Creative Biolabs has an uncompromising commitment to scientific accuracy. Our anti-F8 recombinant antibodies are manufactured under strict quality assurance guidelines. Every lot of our recombinant antibodies is thoroughly validated for purity, specificity, and consistent performance in assay formats relevant to you, ensuring that you receive a reagent of the highest quality.

Fig.1 WB analysis of anti-F8 antibody
(Cat# ZG-0325J, Creative Biolabs).

Customer Reviews

Excellent

D**na
Mouse Anti-F8 Recombinant Antibody (ZG-0325J)

The quality of the antibodies from Creative Biolabs is consistently high. The anti-F8 antibody I’ve tried from Creative Biolabs has worked flawlessly, which is crucial for our work on novel hemophilia therapeutics.

18/Oct/2023

rAb Production

Creative Biolabs is a leader in meeting the needs of the specialized hemophilia research community with a proprietary, state of the art platform. Our anti-F8 recombinant antibodies are expressed in an optimized system that is designed specifically to ensure that these antibodies recognize the large, multi-domain target with high specificity and activity.

Featured Anti-F8 Recombinant Antibody Production Platforms
Fig.2 Milligram-scale anti-F8 recombinant antibody production.

Fig.3 Gram-scale anti-F8 recombinant antibody production.

rAb Modalities

Creative Biolabs is committed to advancing scientific research by offering a variety of flexible antibody modalities. Our anti-F8 recombinant antibodies are available as matched pairs for ELISA, as well as other formats to meet the demands of various applications including diagnostics and research.

Fig.4 Full-length anti-F8 recombinant antibody production and modalities.

F8-Targeted Drug Information

Table 2. Public drug targeting F8.

(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

Creative Biolabs' anti-F8 recombinant antibodies are a valuable addition to any hemophilia researcher’s diagnostic and therapeutic toolbox. We provide the validation and consistency you require to effectively and reliably diagnose F8 deficiency and to monitor inhibitor development in your patients. Contact our scientific team today to learn more about how we can help with your research into this bleeding disorder.